Loading...
•
Sep 30, 2021
Regeneron Q3 2021 Earnings Report
Reported strong financial results driven by growth in revenues and net income.
Key Takeaways
Regeneron reported a strong third quarter in 2021, with total revenues increasing by 51% to $3.45 billion compared to the third quarter of 2020. GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37. The company saw growth in EYLEA U.S. net sales and Dupixent global net sales.
Third quarter revenues increased 51% to $3.45 billion versus third quarter 2020, including $804 million attributable to REGEN-COV.
EYLEA U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion.
Dupixent global net sales increased 55% to $1.66 billion versus third quarter 2020.
GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37.
Revenue by Segment
Forward Guidance
Regeneron's full year 2021 financial guidance includes estimates for R&D, SG&A, gross margin on net product sales, COCM, other operating expense, capital expenditures, and effective tax rate.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...